Duke Cancer InstituteDurham, North Carolina, United States
Disclosure information not submitted.
Paper 66 - CHARACTERIZING THE GENOMIC LANDSCAPE OF MALIGNANT PERIVASCULAR EPITHELIOID CELL FAMILY OF TUMORS IN A REAL-WORLD PATIENT POPULATION USING THE FOUNDATION MEDICINE GENOMIC DATABASE
Friday, November 15, 20244:00 PM – 5:00 PM PST
Paper 77 - A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN + PEMBROLIZUMAB VERSUS DOXORUBICIN ALONE FOR TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND RELATED POORLY DIFFERENTIATED SARCOMAS: ECOG-ACRIN EA7222
Saturday, November 16, 20249:00 AM – 10:00 AM PST
Paper 81 - PEMBROLIZUMAB, RADIOTHERAPY, & SURGERY VS RADIOTHERAPY & SURGERY FOR STAGE III SOFT TISSUE SARCOMA OF THE EXTREMITY: OUTCOMES & SARCOMA IMMUNE CLASS ANALYSIS IN SU2C-SARC032 RANDOMIZED CLINICAL TRIAL
Saturday, November 16, 202410:30 AM – 12:00 PM PST
Paper 84 - PLANNED ANALYSIS OF THE PIVOTAL IGNYTE-ESO TRIAL OF LETE-CEL IN PATIENTS WITH SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA.
Paper 96 - PERSONALIZED CTDNA ANALYSIS IS ASSOCIATED WITH OUTCOMES AFTER PREOPERATIVE RADIOTHERAPY WITH OR WITHOUT PEMBROLIZUMAB FOR STAGE 3 SOFT TISSUE SARCOMAS ON SU2C-SARC032
Saturday, November 16, 20242:00 PM – 3:00 PM PST
Paper 102 - EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND POOR PROGNOSTIC FACTORS: PATIENT-REPORTED OUTCOMES, PROGRESSION-FREE SURVIVAL, AND OBJECTIVE RESPONSE RATE IN THE PHASE 3 DEFI TRIAL
Saturday, November 16, 20243:30 PM – 4:30 PM PST
